Bristol Myers Squibb just announced that RELATIVITY-047 evaluang combinaon of its an-LAG-3 Relatlimab with Opdivo had a significant benefit on progression-free survival. The Phase 2 3 trial in paents with untreated or unresectable melanoma showed a PFS of 10.12 months with the relatlimab combo compared to 4.63 months with Opdivo alone. This is the first me a treatment regimen has shown benefit over PD-1 alone in melanoma. These data to be presented at ASCO (American Society for Clinical O ....
20 May 2021
BMS shows LAG-3 - PD-1 combo boosts PFS in melanoma
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
BMS shows LAG-3 - PD-1 combo boosts PFS in melanoma
Bristol Myers Squibb just announced that RELATIVITY-047 evaluang combinaon of its an-LAG-3 Relatlimab with Opdivo had a significant benefit on progression-free survival. The Phase 2 3 trial in paents with untreated or unresectable melanoma showed a PFS of 10.12 months with the relatlimab combo compared to 4.63 months with Opdivo alone. This is the first me a treatment regimen has shown benefit over PD-1 alone in melanoma. These data to be presented at ASCO (American Society for Clinical O ....